schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".

.

another new drug in the migraine pipeline is lasmiditan. it works the same way as triptans. but unlike the triptans, it doesn't constrict.

eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..copyright © 2018 the daily californian, the independent berkeley student publishing co., inc..

capgemini employees' rant on hike light up social media